# Y-mAbs (YMAB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/YMAB
## Company Profile
- Ticker: YMAB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Antibody Drugs, Oncology
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
Y-mAbs Therapeutics is an oncology and rare-disease company focused on antibody-based therapies. Its platform has been built around highly specific biologic treatments for difficult diseases.
## Why The Stock Is Moving

Current closing-price context is not available for YMAB.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Y-mAbs sits in specialty biotechnology.

## Business Model

The company depends on product adoption, clinical progress, and the expansion of its antibody franchise.

## Landscape Position

Y-mAbs is a focused antibody biotech whose stock reacts to data, adoption, and label progress.

## Future Catalysts

- Y-mAbs’s catalysts are DANYELZA sales, pediatric-oncology expansion, and any follow-on immunotherapy update. The key question is whether the GD2 franchise can keep compounding.

## Recent News
- 2025-09-16 12:41 EST — [SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics](https://biopharmsignal.com/news/YMAB/serb-pharmaceuticals-completes-acquisition-of-y-mabs-therapeutics) — Source: Y-mAbs
- 2025-08-08 10:35 EST — [Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments](https://biopharmsignal.com/news/YMAB/y-mabs-reports-second-quarter-2025-financial-results-and-recent-corporate-developments) — Source: Y-mAbs
- 2025-08-07 11:30 EST — [Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025](https://biopharmsignal.com/news/YMAB/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025) — Source: Y-mAbs
- 2025-08-05 12:30 EST — [SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics](https://biopharmsignal.com/news/YMAB/serb-pharmaceuticals-agrees-to-acquire-y-mabs-therapeutics) — Source: Y-mAbs
- 2025-05-28 10:35 EST — [Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline](https://biopharmsignal.com/news/YMAB/y-mabs-hosts-virtual-radiopharmaceutical-randd-update-highlighting-clinical-progress-and-expanded-pipeline) — Source: Y-mAbs